Video Experimental Relacionado
Updated: Jul 22, 2026
11:36
Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
Published on: April 21, 2012
La resistencia a la aspirina es la resistencia a la aspirina
Graeme J Hankey1, John W Eikelboom
1Department of Neurology, Royal Perth Hospital and School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia.
Lancet (London, England)
|February 21, 2006
Resumen
La resistencia a la aspirina, donde la aspirina no inhibe la activación plaquetaria, puede aumentar el riesgo de eventos cardiovasculares. Comprender sus causas y su detección es clave para superar esta condición.
Área de la Ciencia:
- Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
- Farmacología Farmacología.
Sus antecedentes:
- La resistencia a la aspirina se define como la incapacidad de la aspirina para inhibir adecuadamente la producción plaquetaria de tromboxano A2.
- Esta resistencia está relacionada con un mayor riesgo de eventos cardiovasculares.
- Las pruebas de laboratorio pueden detectar la resistencia a la aspirina mediante la evaluación de la producción o función de tromboxano A2 en las plaquetas.
Objetivo del estudio:
- Explorar las causas e implicaciones de la resistencia a la aspirina.
- Revisar los métodos para detectar la resistencia a la aspirina.
- Para discutir estrategias para superar la resistencia a la aspirina.
Principales métodos:
- Revisión de la literatura de los estudios sobre la resistencia a la aspirina.
- Análisis de las posibles causas, incluyendo dosis inadecuadas, interacciones farmacológicas y factores genéticos.
- Examen de las pruebas de laboratorio de diagnóstico para la función plaquetaria.
Principales resultados:
- Se identificaron múltiples causas de resistencia a la aspirina: dosificación inadecuada, interacciones farmacológicas, variaciones genéticas (polimorfismos de COX-1), aumento de la producción de tromboxano de fuentes no plaquetarias y aumento de la rotación de plaquetas.
- Se confirmó que la resistencia a la aspirina se puede detectar a través de ensayos de laboratorio específicos.
- Destacó la correlación entre los crecientes grados de resistencia a la aspirina y un mayor riesgo de eventos cardiovasculares.
Conclusiones:
- La resistencia a la aspirina es un problema clínico significativo asociado con un mayor riesgo cardiovascular.
- Abordar las causas subyacentes y utilizar las pruebas de diagnóstico adecuadas son cruciales para controlar la resistencia a la aspirina.
- La investigación futura debe centrarse en refinar las definiciones, mejorar la precisión del diagnóstico y evaluar las intervenciones terapéuticas.
Videos de Conceptos Relacionados
00:42Cross-reactivity
Overview
01:25Dose-Response Relationship: Selectivity and Specificity
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
01:13Therapeutic Index
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
01:30Combined Effects of Drugs: Antagonism
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
01:24Tissue-Drug Binding: Localization of Drugs and its Significance
Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine the...
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine the...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...